Choose A when
Tirzepatide
For research with an approved compound and accessible clinical protocols.
See full profileComparison
Both peptides are from Eli Lilly — Tirzepatide is the dual GLP-1/GIP agonist (approved), Retatrutide is the triple GLP-1/GIP/glucagon agonist (Phase 3). The comparison is between the established standard and its successor.
| Spec | A Tirzepatide | B Retatrutide |
|---|---|---|
| Mechanism | GLP-1 + GIP dual | GLP-1 + GIP + glucagon triple |
| Weight loss | 22.5% / 72 weeks | 24.2% / 48 weeks |
| Regulatory status | FDA approved (2022/2023) | Phase 3 (TRIUMPH-1, expected 2026-2027) |
| Additional effect | GIP — thermogenesis, lipid metabolism | Glucagon — energy expenditure, hepatic lipolysis |
| Side effects | GI (nausea, vomiting), known | GI + higher heart rate from glucagon component |
Choose A when
For research with an approved compound and accessible clinical protocols.
See full profileChoose B when
For exploring the newest generation of metabolic peptides and the triple mechanism.
See full profileVerdict
Retatrutide is stronger on absolute weight loss but Tirzepatide is fully approved — for production protocols, that matters.
Other comparisons